Keywords
MedicineFluvastatinRosuvastatinEzetimibePravastatinStatinAtorvastatinLovastatinCost effectivenessCholestyramineSimvastatinPharmacotherapyInternal medicineHMG-CoA reductaseCholesterolAdverse effectPopulationPharmacologyReductaseEnvironmental health
Affiliated Institutions
Related Publications
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial)
The primary objective of this 6-week, parallel-group, open-label, randomized, multicenter trial was to compare rosuvastatin with atorvastatin, pravastatin, and simvastatin acros...
Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis
Statins can lower LDL cholesterol concentration by an average of 1.8 mmol/l which reduces the risk of IHD events by about 60% and stroke by 17%.
Comparison of Once-Daily, niacin Extended-Release/lovastatin with standard doses of atorvastatin and simvastatin (the advicor versus other Cholesterol-Modulating agents trial evaluation [ADVOCATE])
This study compared the relative efficacy of a once-daily niacin extended-release (ER)/lovastatin fixed-dose combination with standard doses of atorvastatin or simvastatin, with...
Effects of Fibrates on Metabolism of Statins in Human Hepatocytes
This study investigated the metabolic interaction between fibrates and statin hydroxy acids in human hepatocytes. Gemfibrozil (GFZ) modestly affected the formation of beta-oxida...
Publication Info
- Year
- 2010
- Type
- article
- Volume
- 10
- Issue
- 6
- Pages
- 369-382
- Citations
- 31
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
31
OpenAlex
Cite This
Pedro Plans-Rubió
(2010).
The Cost Effectiveness of Statin Therapies in Spain in 2010, after the Introduction of Generics and Reference Prices.
American Journal of Cardiovascular Drugs
, 10
(6)
, 369-382.
https://doi.org/10.2165/11539150-000000000-00000
Identifiers
- DOI
- 10.2165/11539150-000000000-00000